Epoch 13: Man vs Machine - Automating Venture Capital

Investing, Statistics, Man vs Machine

Welcome to the 12 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1,104 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar!  Welcome back for another week of biotech analysis. This week we discuss the topic of Automating Venture Capital.  We recently came across a few papers where the authors looked to follow-up on different innovation contests, judged by industry experts (including VCs) to see if there were specific features that could be used to pick winners early on.  The hypothesis would be that if there was predictive power in a handful of the identified variables, we could do away with human VC and construct funds purely based on math.  An interesting exercise, but far from ready for prime time!

BowtiedBiotech is now operating under a hybrid subscription model where the Sunday update has moved under the paywall - a BIG THANK YOU to those that have joined. The Thursday market update will continue to remain free. The more forward looking content, the insider insights, and market data you need to really assess what is happening in the world of biotech will shift to Sundays. 

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

Go forward we will be making announcements regarding significant public biotech trading opportunities via substack ALERT special posts.  This will focus primarily on the major market moving biotech events and will likely be centered around data readouts from the major scientific conferences.  We will not offer trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely drive stock prices +/-100% in either direction.  Be sure to SUBSCRIBE to not miss.

Enough shilling for the day, lots to cover this week, let's get started!